09
Feb

Alkermes says its researchers nailed down the efficacy and safety data it needed from an early-stage study of ALKS 8700, its new-and-improved rival to the blockbuster multiple sclerosis drug Tecfidera from Biogen Idec. And now the transatlantic biotech plans to shift its drug straight into a pivotal study in search of a relatively swift approval.

…read more

Source: Alkermes says its more tolerable Tecfidera rival is ready for pivotal challenge

    

0 No comments